logo-loader
viewSona Nanotech

Sona Nanotech secures manufacturing service deal, inks LOI for 2M coronavirus tests

For the moment, the test is still in development, but Sona expects to complete a functional prototype and confirm third-party validation tests in the near future

Person wearing scrubs and gloves with microscope
Sona's test is designed to detect the presence of the virus itself, rather than detecting antibodies that present after infection

Sona Nanotech Inc (CSE:SONA) (OTCPINK:SNANF) has moved one step closer to getting a rapid-response coronavirus (COVID-19) detection test on the market by entering into service and supply agreements with a European contract manufacturing organization.

The company also signed a letter of intent (LOI) agreement for the purchase of 2 million kits with an international distributor representing a G20 country. The price will be agreed upon following validation of the test, the company said.

For the moment, the test is still in development, but Sona expects to complete a functional prototype and confirm third-party validation tests in the near future. What makes it unique, though, is that it’s designed to detect the presence of the virus itself, rather than detecting antibodies that present after infection, which can lead to false positives and false negatives.

READ: Humanigen poised to partner with leading contract research organization on Phase III trial to tackle deadly coronavirus

The deals represent firm commitments for the Halifax, Nova Scotia company to fund the manufacturing, set-up and transfer of its test technology. Sona has applied for funding from the Candian government for the advanced development of a test prototype and to accelerate manufacturing scale-up. 

Actual manufacturing will begin once firm orders with deposits have been received.

In developing the prototype, Sona is working with a consortium of Canadian and international partners, including GE Healthcare Life Sciences, The Native Antigen Company, AffinityImmuno, Bond Digital Health, as well as scientific advisors Fiona Marshall and Sandy Morrison.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Sona Nanotech

Price: 1.64 CAD

CSE:SONA
Market: CSE
Market Cap: $98.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: XPhyto sees Germany as key market as they announce deal with...

XPhyto (CSE: XPHY- OTC: XPHYF) CEO Hugh Rogers and Bunker, Managing Director Wolfgang Probst joined Steve Darling from Proactive Vancouver to share news the company has signed a deal with German Brewer Oettinger development, production, and distribution of cannabis-infused beverages and...

2 days, 11 hours ago

2 min read